A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

This study is testing a new drug called LBL-024 — either alone or in combination with other medications — for people with triple-negative breast cancer (a type of breast cancer that does not respond to hormone therapies). **You may be eligible if...** - You are 18 or older - You have been diagnosed with triple-negative breast cancer - You have at least one tumor that can be measured on imaging scans - Your general health and ability to function is rated as good (ECOG score 0–1) - Your expected survival is at least 12 weeks - If you can become pregnant, you agree to use highly effective contraception from consent through 6 months after the last dose **You may NOT be eligible if...** - You do not have measurable disease - You have significant organ dysfunction - You are pregnant or unwilling to use contraception - You do not meet the health requirements set out in the study protocol Talk to your doctor to see if this trial is right for you.